A high-level overview of federal agency priorities and initiatives, and criminal investigations and enforcement trends for the life sciences industry.
- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Banking and Institutional Finance
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Crisis Management
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
News & Insights
Article
March 11, 2021
Biden Administration - What's Ahead for the Life Sciences Industry?
Featured Lawyers
Amanda J. Klingler
Washington, D.C.
Kristen Renee Fournier
New York
Elaine H. Tseng
San Francisco
Adam C. Solander
Washington, D.C.
Lisa M. Dwyer
Washington, D.C.
Mark A. Jensen
Washington, D.C.
Close
Featured Lawyers
Amanda J. Klingler
Washington, D.C.
Kristen Renee Fournier
New York
Elaine H. Tseng
San Francisco
Adam C. Solander
Washington, D.C.
Lisa M. Dwyer
Washington, D.C.
Mark A. Jensen
Washington, D.C.
Ethan P. Davis
San Francisco
Michael R. Pauze
Washington, D.C.
Mark S. Brown
Washington, D.C.
Lana K. Varney
Austin
Andrew T. Bayman (Andy)
Atlanta
Jessica Ringel
Washington, D.C.
Derek Meilman
London
D. Kyle Sampson
Washington, D.C.
Daniel F. Donovan (Dan)
Washington, D.C.
John D. Shakow
Washington, D.C.
Wick Sollers
Washington, D.C.
Seth H. Lundy
Washington, D.C.
Brandt Leibe
Houston
Theodore M. Hester (Ted)
Washington, D.C.
Thomas E. Keim, Jr. (Ted)
Chicago
Nikki Reeves
Washington, D.C.
Harold E. Franklin, Jr.
Atlanta
